M. Groschek

发表

A prospective observational study of anaemia management in cancer patients - results from the German Cancer Anaemia Registry.

H. Tesch, A. Tsamaloukas, U. Totzke, 2011, European journal of cancer care.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange

U. Germing, A. Junkes, N. Gattermann, 2012, European journal of haematology.

Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry

M. Stauch, J. Trojan, R. Hofheinz, 2020, International journal of cancer.

Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma

M. Grimm, T. Steiner, E. Herrmann, 2011, World Journal of Urology.

Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression

M. Schuler, A. Bankfalvi, M. Wiesweg, 2020, Cancer medicine.

KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).

W. Weichert, A. Stenzinger, Michael Thomas, 2021, Lung cancer.

Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR

H. Eschenburg, C. Gessner, A. Kretzschmar, 2022, Current medical research and opinion.

Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia--examination of practice in Germany.

H. Tesch, S. Schmitz, A. Tsamaloukas, 2008, Current Medical Research and Opinion.

Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non‐interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials

H. Eschenburg, W. Knauf, T. Dechow, 2021, European journal of haematology.

Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia – examination of practice in Germany

H. Tesch, A. Tsamaloukas, U. Totzke, 2008 .

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

C. Kortsik, T. Trarbach, W. Brueckl, 2023, JTO clinical and research reports.

Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.

M. Grimm, T. Steiner, E. Herrmann, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.